GKOS:NYE-Glaukos Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 106.51

Change

0.00 (0.00)%

Market Cap

USD 1.10B

Volume

0.51M

Analyst Target

USD 48.89
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-04 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.28 (-0.27%)

USD 182.35B
SYK Stryker Corporation

+5.42 (+1.64%)

USD 127.50B
MDT Medtronic PLC

+0.91 (+1.12%)

USD 112.21B
BSX Boston Scientific Corp

+1.25 (+1.68%)

USD 109.35B
EW Edwards Lifesciences Corp

+0.52 (+0.59%)

USD 53.72B
PHG Koninklijke Philips NV ADR

+0.47 (+1.77%)

USD 26.22B
ZBH Zimmer Biomet Holdings Inc

+0.56 (+0.48%)

USD 24.72B
STE STERIS plc

+2.36 (+1.04%)

USD 22.99B
SNN Smith & Nephew SNATS Inc

+0.22 (+0.89%)

USD 11.41B
GMED Globus Medical

+0.43 (+0.66%)

USD 8.83B

ETFs Containing GKOS

AWEG The Alger ETF Trust 3.77 % 0.00 %

+0.25 (+1.09%)

USD 4.69M
WELL:LSE Hanetf Icav - Han-Gins He.. 1.32 % 0.00 %

+0.01 (+1.09%)

USD 0.02B
AGED:LSE iShares Ageing Population.. 0.73 % 0.00 %

+0.02 (+1.09%)

USD 0.48B
AGES:LSE iShares IV Public Limited.. 0.73 % 0.00 %

-0.25 (1.09%)

USD 0.48B
2B77:F iShares Ageing Population.. 0.72 % 0.00 %

N/A

N/A
2B77:XETRA iShares Ageing Population.. 0.71 % 0.00 %

-0.01 (1.09%)

USD 0.50B
ETHO Etho Climate Leadership U.. 0.00 % 0.45 %

+0.40 (+1.09%)

USD 0.18B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

+0.34 (+1.09%)

USD 0.21B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

+0.80 (+1.09%)

USD 0.26B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.99% 91% A- 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.99% 91% A- 97% N/A
Trailing 12 Months  
Capital Gain 95.47% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.47% 94% A 97% N/A
Trailing 5 Years  
Capital Gain 40.81% 70% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.81% 65% D 63% D
Average Annual (5 Year Horizon)  
Capital Gain 18.54% 84% B 83% B
Dividend Return 18.54% 84% B 81% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.53% 23% F 17% F
Risk Adjusted Return 34.00% 74% C 56% F
Market Capitalization 1.10B 59% D- 76% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 42.30 17% 5%
Price/Book Ratio 10.52 9% 7%
Price / Cash Flow Ratio -85.38 100% 98%
Price/Free Cash Flow Ratio -60.25 97% 97%
Management Effectiveness  
Return on Equity -27.16% 34% 12%
Return on Invested Capital -16.66% 32% 9%
Return on Assets -7.96% 34% 9%
Debt to Equity Ratio 61.24% 27% 55%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector